Approximately 10-30% of patients with NSCLC harbor EGFR mutations, mainly in exons 18-21, which are considered to be oncogenic drivers and highly promote EGFR downstream signaling pathways (9). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.